MedTrace Logo

Annatto-derived GG for Statin-associated Myopathy

NCT05312424 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2025-09-12

No results posted yet for this study

Summary

To evaluate the effects of 3-months annatto-derived geranylgeraniol (GG) supplementation on statin-associated skeletal muscle health.

Conditions

  • Myopathy; Primary

Interventions

DIETARY_SUPPLEMENT

Placebo

300 mg olive oil

DIETARY_SUPPLEMENT

Low GG

150 mg GG

DIETARY_SUPPLEMENT

High GG

300 mg GG

Sponsors & Collaborators

  • Texas Tech University Health Sciences Center

    lead OTHER

Principal Investigators

  • Chwan-Li (Leslie) Shen, PhD · Texas Tech Health Science Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-15
Primary Completion
2027-06-30
Completion
2027-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05312424 on ClinicalTrials.gov